If you have IBS and you have seen the posts claiming that Mounjaro "stopped" years of diarrhea, you are probably asking the sensible question: is that real, and could it happen to me? The honest answer is that nobody knows yet. No randomized trial has tested tirzepatide (Mounjaro, Zepbound) or semaglutide (Ozempic, Wegovy) as a treatment for IBS. What exists is a mix of gut physiology studies, weight-loss and diabetes trials that record side effects, a small amount of older IBS research on a related drug, and a very new observational analysis.
This guide walks through all of it in plain English: what the evidence supports, what it does not, and why the same drug class can plausibly calm one person's IBS-D and worsen another person's IBS-C. It describes evidence only. Whether you should start, stop or change any medicine is a decision for you and your prescriber, and nothing here is advice to do any of those things.
Can Mounjaro help IBS?
Possibly for some people, but it has not been shown. Mounjaro is licensed for type 2 diabetes and its weight-loss version for obesity, not for IBS. The strongest direct IBS evidence so far is a 2026 observational analysis, and observational means it cannot separate the drug from everything else that changes when someone starts it.
Here is what that study actually did. Researchers used a large network of electronic health records and identified people with an IBS diagnosis who started a GLP-1 drug (semaglutide, liraglutide, dulaglutide, exenatide or tirzepatide) within 90 days of diagnosis. They matched them to people with IBS who did not. In the 90-day analysis, with about 6,665 people per group, the GLP-1 group had lower rates of coded chronic diarrhea (8.9% versus 10.6%), chronic constipation (19.8% versus 22.0%), abdominal pain (31.6% versus 35.8%) and bloating or distension (8.3% versus 10.9%). Similar patterns appeared in the IBS-D and IBS-C subgroups (Khan 2026).
Those are real signals, and they are also small. The gaps are one to four percentage points. The outcomes are billing codes, not symptom diaries. The people who start a GLP-1 drug are usually being treated for diabetes or obesity, so they differ from people who do not in ways matching cannot fully remove. The authors themselves describe the results as hypothesis-generating and say prospective studies are needed (Khan 2026).
The most useful framing comes from Michael Camilleri and Alexander Ford, who reviewed the question in Gastroenterology in 2026. They conclude there is "considerable potential" for these drugs to affect gut motor and sensory function relevant to IBS, but that there are no published data on the magnitude of transit effects or on whether a person's bowel function before treatment predicts which way the drug pushes. They argue proof-of-concept studies should come before large randomized trials (Camilleri 2026).
So the accurate answer to "can Mounjaro help IBS?" is "it might, and for whom and how much is unknown". If someone tells you it definitely will, they are going beyond the evidence.
Why might GLP-1 drugs change IBS-D?
Because GLP-1 acts on the gut itself, not only on appetite. GLP-1 is a hormone the gut releases after eating. Drugs that copy it, and tirzepatide, which copies GLP-1 and a second hormone called GIP, have measurable effects on how the digestive tract moves. There are at least four plausible routes to a change in IBS-D, and the evidence for each is different.
1. Slower stomach emptying
Delayed gastric emptying is the best-established effect. In a pharmacology study including people with and without type 2 diabetes, a single dose of tirzepatide delayed gastric emptying, similar to long-acting GLP-1 drugs. In healthy participants the effect faded after repeated doses, while people with type 2 diabetes still showed a residual delay at later doses (Urva 2020). That tapering is called tachyphylaxis, and it is why gut side effects often fade with time. Camilleri and Ford also note that in one 16-week randomized trial in non-diabetic people with obesity, up to 40% never had a delay in gastric emptying at all (Camilleri 2026).
Be careful with the intuitive story that slower stomach emptying equals less diarrhea. IBS-D is not simply a fast-stomach problem, and gastric emptying is only the first stop.
2. Slower small bowel movement
When researchers infused GLP-1 into healthy volunteers and into people with IBS and recorded pressure along the stomach and small bowel, GLP-1 reduced the migrating motor complex, the housekeeping wave of contractions that sweeps the small bowel between meals. It did so in both groups (Hellstrom 2008). Dampening small bowel propulsion is a reasonable candidate for reducing urgency and frequency in some people with IBS-D. Notably, this was an intravenous infusion of the natural hormone, not a weekly drug, so it shows what GLP-1 can do, not what Mounjaro does at a given dose.
3. Colon transit, which goes both ways
This is where the story stops being tidy. The colon is where IBS bowel habit is largely decided, and the effects of GLP-1 drugs there are mixed. Camilleri and Ford tabulate the findings: retrospective studies of people having transit tests found delayed colonic transit in roughly 30% of people on a GLP-1 drug versus about 20% of those not on one, and a capsule-based case series found prolonged whole-gut transit in over 40%. In contrast, a randomized trial of liraglutide in people with type 1 diabetes and nerve damage found shorter large bowel transit time versus placebo, and in IBS-C patients the ROSE-010 analog accelerated colonic transit at 48 hours (Camilleri 2026). The retrospective figures come from people being tested for symptoms, who are not a random sample of everyone taking these drugs.
The lesson is that the same drug class appears able to slow the colon in some people and speed it in others. That is consistent with the reality that both diarrhea and constipation are listed side effects.
4. Pain signaling
GLP-1 receptors are present on sensory nerve cells that carry gut signals, and animal and early human work suggests GLP-1 drugs may dampen visceral pain pathways. In rodent models, GLP-1 agonists reduced visceral hypersensitivity. Camilleri and Ford summarize this as a potential, not a proven, benefit in IBS (Camilleri 2026). The human data on pain come mostly from the ROSE-010 trials covered below.
What about eating less, weight loss and inflammation?
People in online threads often point to weight loss, eating less, or an "anti-inflammatory effect" as the reason. Those are plausible and untested for IBS specifically. A 2026 review of GI side effects lists the physiological effects of rapid weight loss itself as one mechanism behind the gut symptoms people get on these drugs (Singhani 2026), which cuts both ways. Smaller meals could mean less stimulus to a sensitive gut, and rapid weight loss could add its own symptoms. Nobody has separated these effects in an IBS trial.
A related question: is it IBS-D or bile acid diarrhea?
Some of the dramatic IBS-D stories may involve a different condition. Bile acid diarrhea (also called bile acid malabsorption) mimics IBS-D and is frequently misdiagnosed as it. In a 2022 randomized, double-blind trial of 52 people with confirmed bile acid diarrhea, 77% on liraglutide had a 25% or greater drop in stool frequency, versus 50% on the standard treatment colesevelam. It was a non-inferiority trial that happened to show superiority, it was small and short, and the authors called for larger confirmatory trials (Karhus 2022). Our guide to bile acid malabsorption versus IBS explains how it is tested and why it is worth raising if usual IBS-D care has never worked.
Can Mounjaro or Ozempic make IBS worse?
Yes, it can, because gut side effects are the most common problem with the whole class. Nausea, vomiting, diarrhea and constipation were all more frequent than placebo in the two big obesity trials, and neither trial was designed around people with IBS.
The pivotal trials report that gastrointestinal events were the most common adverse events, mostly mild to moderate, occurring mainly during dose escalation, and settling with time. In SURMOUNT-1, adverse events caused people to stop in 4.3%, 7.1% and 6.2% across the three tirzepatide doses versus 2.6% on placebo (Jastreboff 2022). In STEP 1 of semaglutide, 4.5% stopped for gastrointestinal events versus 0.8% on placebo (Wilding 2021).
A 2026 narrative review tabulated the specific symptom rates from those papers. The figures below are the highest tirzepatide dose in SURMOUNT-1 and the semaglutide dose in STEP 1, drug versus placebo:
| Symptom | Tirzepatide, SURMOUNT-1 | Semaglutide, STEP 1 |
|---|---|---|
| Nausea | 31% vs 11% | 44% vs 16% |
| Vomiting | 13% vs 2% | 25% vs 6% |
| Diarrhea | 23% vs 10% | 30% vs 16% |
| Constipation | 15% vs 5% | 24% vs 11% |
Source: tabulated in Singhani 2026, drawn from Jastreboff 2022 and Wilding 2021. The two trials used different populations and schedules, so the columns are not a head-to-head comparison.
Two cautions follow. First, those were people recruited for weight loss, not people with IBS, whose guts may react differently. Second, the trials tell you the average experience, and averages hide people who had a very rough time and people who had no gut effects at all.
What happens in IBS in the real world? One hospital study of 256 people with IBS who had been prescribed more than one GLP-1 drug found that those with mixed-type IBS switched agents most often (about 22%), followed by IBS-C (about 12%) and IBS-D (about 2%). Stops linked to symptoms such as nausea, vomiting, diarrhea or constipation rose from 28% on the first drug to 30% on the second and 48% on the third. Switching was common, and semaglutide users were more likely than liraglutide users to stop within six months (63% versus 43%) (Gautam 2025). It is a single-center retrospective study, so treat it as a pattern worth knowing, not a rate to expect.
Camilleri and Ford draw out the logical point: because diarrhea and constipation are both effects of these drugs, bowel function in IBS could be improved or aggravated. A drug that slows the colon may help IBS-D and make IBS-C worse. They also note it could aggravate nausea and vomiting in people whose IBS overlaps with functional dyspepsia (Camilleri 2026).
An expert consensus document exists on how clinicians manage gut side effects in people taking these drugs (Gorgojo-Martinez 2022). Those decisions about timing, escalation and what to do if symptoms flare belong to the person who prescribed it, which is why the rest of this guide keeps pointing you back to that conversation.
Is there research on GLP-1 drugs specifically in IBS?
Yes, but it is thin, mostly old, and about a different drug. To be completely explicit: there is no large randomized, placebo-controlled trial of a weight-loss GLP-1 drug in IBS. Here is everything that does exist.
1. The ROSE-010 trials (as-needed pain relief). ROSE-010 is a GLP-1 analog that was tested as an injection for sudden pain attacks in IBS, not as a daily or weekly treatment. In a randomized, double-blind, placebo-controlled crossover trial of 166 people meeting Rome II criteria, about twice as many people were responders for pain relief after ROSE-010 as after placebo (24% and 23% on the two doses versus 12%) (Hellstrom 2009). A later cross-analysis of the same data found pain relief was greatest in IBS-C and mixed IBS, and less in IBS-D, and that higher doses brought more nausea (Touny 2022).
2. The 2025 meta-analysis. A systematic review and meta-analysis pooled the ROSE-010 data and reported that the lower dose tested reduced pain intensity versus placebo (odds ratio 2.30, 95% CI 1.53 to 3.46), with more nausea, vomiting and headache. The authors say the effect on different IBS subtypes and long-term effects need further investigation (Mostafa 2025). It is worth noting that this pooled a very small number of trials of one analog, so it says little about Mounjaro itself.
3. A mechanistic trial in IBS-C. In a small randomized study of 46 women with IBS-C, ROSE-010 delayed gastric emptying of solids and did not retard colonic transit at 24 hours, but sped it up at 48 hours with the lower doses, with nausea and vomiting as side effects (Camilleri 2012).
4. The 2025 prescribing study of 256 people with IBS described above (Gautam 2025).
5. The 2026 observational analysis of GLP-1 drugs in IBS (Khan 2026).
6. Expert commentary. Camilleri and Ford note that trials of a dual GLP-1 and GIP agonist in IBS are ongoing (Camilleri 2026). Those results are not available at the time of writing.
What is missing is a prospective trial in which people with a Rome-criteria IBS diagnosis, sorted by subtype, are randomly assigned to a weight-loss GLP-1 drug or placebo and followed on symptom scores, stool form and pain. Until that exists, everything above is suggestive, not conclusive.
Mounjaro and IBS-C
For IBS-C the picture is less encouraging on paper, because constipation is a listed side effect. In the obesity trials, constipation was reported by 15% of people on the top tirzepatide dose versus 5% on placebo, and by 24% versus 11% with semaglutide (Singhani 2026). IBS-C already means hard, lumpy stools more than a quarter of the time on abnormal days under the Rome IV rule (Mearin 2016), so a drug that adds slowing is a reasonable worry. Our guide to the difference between IBS-D and IBS-C explains how subtype is assigned and why it can shift.
There are complicating findings. A 2026 study cited by Camilleri and Ford found about 30% of people on GLP-1 drugs reported constipation compared with 26% of people with obesity on other weight-loss drugs, yet the incidence was actually lower for GLP-1 drugs (3.34 versus 3.73 per 100 person-years), a "higher rate, lower incidence" pattern the reviewers called confusing (Camilleri 2026). The ROSE-010 work found accelerated colonic transit at 48 hours in IBS-C (Camilleri 2012), and pain relief tended to be greatest in IBS-C and mixed IBS (Touny 2022). In the 2026 observational study, people in the IBS-C subgroup had lower rates of coded abdominal pain and bloating after GLP-1 initiation (Khan 2026).
Put together: for IBS-C the research does not say the drugs will constipate you, and it does not say they will help. It says the outcome is not predictable, which is exactly why watching and recording what your own bowels do matters. Do not add laxatives, fiber supplements or anything else on your own to counter a change without asking your prescriber or pharmacist, since the right response depends on what is actually happening. Our guide to what to eat with IBS-C covers the food side for IBS-C generally.
What do people with IBS actually report?
A split picture, with a lot of enthusiasm and a fair amount of disappointment. Reading threads is useful for finding the questions to ask, so long as it stays in that role.
The most active recent discussion is a post in r/ibs where someone described Mounjaro seeming to stop four years of IBS-D, with about 111 comments (r/ibs thread). Several themes come up repeatedly:
- Many replies describe a big drop in urgency, cramping and frequency, some within days of starting, across tirzepatide, semaglutide and a daily tablet form.
- A few describe a swing in the other direction, such as mixed bowel habit or a week of daily diarrhea, and one describes being advised by a clinician to stop.
- Some report that the benefit faded or returned after stopping, and others say a new problem such as constipation or reflux appeared.
- People raise theories: slower transit, inflammation, immune effects, or simply eating much less. Others point out the same IBS can have a different underlying cause, such as bile acid problems or microscopic colitis, which is a good reason to ask about testing.
- Cost and access come up constantly, including people wishing a doctor could prescribe it for IBS.
There are other r/ibs threads on the same question, including one titled "Anyone with IBS tried GLP1 drugs?" and another from someone describing severe constipation after starting Mounjaro (r/ibs search results). The existence of both tells you something the trial tables do too: the experience varies.
What Reddit cannot do is tell you how common each experience is, whether the drug caused it, or whether your gut will respond the same way. People who feel dramatically better are more likely to post, and stories rarely include the testing that would show whether the original diagnosis was right.
What to track if you have IBS and start a GLP-1
Track bowel form, timing, symptoms, food and the exact timing of any medication change, in one place, with dates. Gut effects of these drugs tend to cluster around initiation and dose changes, so a log that shows what changed and when is far more useful to a prescriber than "I feel different".
Here is what is worth recording, and why.
- Every stool, by Bristol type. The Bristol scale is a validated guide to transit time (Lewis 1997). It lets you see whether things are drifting toward hard (types 1 and 2) or loose (types 6 and 7), and counts matter more than impressions. For background on why recalled bowel habit is unreliable and how to count, see our guide on how to track IBS symptoms without an app.
- Urgency, and whether you can make it to the toilet. Frequency can fall while urgency stays, or the reverse.
- Night-time symptoms. Waking at night with diarrhea or pain is a reason to speak to a doctor.
- Blood or mucus. Blood needs medical attention promptly, whatever else is going on.
- Pain, bloating, nausea and vomiting, with a simple 0 to 10 score. Nausea and vomiting are among the most common effects, and timing relative to meals and dose day is informative.
- Appetite and how much you are eating. If a drop in intake coincides with better bowels, that is worth knowing, and equally if you are barely eating.
- Medication, including the date of each injection or dose change, any missed dose, and every other medicine or supplement you use for bowels. Laxatives, loperamide, magnesium and others distort the picture. Record them; do not stop them to get a cleaner log without asking.
- Meals, only as much as you can sustain. A simple "what I ate" entry is enough.
A worked example of how this reads to a clinician: if the log shows four loose stools a day before the first dose, two softer stools a day in weeks one to three, and then a run of type 1 stools with bloating after a dose step, you have shown a pattern linked to a dated event. That is more actionable than a general impression and gives your prescriber something concrete to weigh.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
If you would rather log on your phone, Clairop (iPhone only, free to download, using it needs a Clairop Pro subscription) records stools with one-tap Bristol entries including urgency, blood, mucus and night-time detail, alongside meals, symptoms and medication, and produces a one-page visit report labeled as patient-entered data. It is not a medical device, is not diagnostic and has not been clinically validated, and it will not tell you whether a medicine is working. Its food trigger analysis only shows results after at least five meals with and five without a food, which is a limitation to bear in mind when changes are recent. See how it works for details. A paper diary does the same job if you prefer it.
Questions to bring to the prescriber
These are questions, not recommendations about what to do:
- I have IBS, with mostly diarrhea, constipation or mixed pattern. How might that affect how I respond?
- What should I do, and who should I contact, if bowel symptoms get worse after a change?
- Which symptoms would you want to hear about the same day?
- Has anyone considered whether my IBS-D could be bile acid diarrhea, or tested for celiac disease or inflammation if that has not been done?
- I take other bowel medicines or supplements. How should we handle those alongside this?
- I have an endoscopy or procedure coming up. Who tells the procedure team about this medicine?
That last one matters. These drugs slow gastric emptying, which can leave food in the stomach and may raise aspiration risk during upper endoscopy or anesthesia, although some studies found actual aspiration is uncommon (Jalleh 2026). Camilleri and Ford note that guidance on managing the drug before elective endoscopy should be followed (Camilleri 2026). Always tell the procedure team about every GLP-1 drug you take, and let them tell you what to do.
When to see a doctor promptly
IBS symptoms can overlap with conditions that need treatment, and these drugs have their own warning signs. See a doctor promptly, and do not wait for your next scheduled review, if you have:
- Blood in your stool, or black, tarry stools
- Weight loss beyond what your prescriber expected, or loss with no explanation
- Fever
- Waking at night with diarrhea or pain
- Persistent vomiting, or being unable to keep fluids down
- Severe or worsening abdominal pain, especially with a swollen abdomen
- Signs of dehydration, such as dizziness, very dark urine or a very dry mouth
- Symptoms starting after age 50, or a family history of bowel cancer or inflammatory bowel disease
- Anemia, or constant tiredness with other symptoms
Severe, unrelenting abdominal pain, with or without vomiting, deserves urgent care in its own right.
Myths worth correcting
"It treats IBS." It is not approved or proven for IBS. The research above is early and partly observational.
"If it fixes my IBS-D, it was never real IBS." Not necessarily. A drug can reduce symptoms without telling you anything about the original diagnosis, though it can be worth asking whether another cause was missed.
"The side effects always settle." In the trials they were mostly mild to moderate and most common at escalation, but for some people they led to stopping (Wilding 2021).
"Low FODMAP is no longer needed." The IBS guideline position is not changed by any of this. The low FODMAP diet remains a short structured process with reintroduction, ideally with a dietitian. If you are eating much less than before, get advice before restricting more foods.
"Reddit success stories show what will happen to me." They show what happened to some people who chose to post. That is a reason to ask your clinician, nothing more.
Bottom line
The evidence supports three statements. These drugs change gut movement. Diarrhea and constipation are both common effects. And early IBS-specific data hint at benefit for some people but do not yet show who, how much or why. If you have IBS and are considering or already taking a GLP-1 drug, the practical steps are modest: keep a dated log of stools, symptoms and medication, report worsening promptly, mention the drug to every clinician and procedure team, and make any decision about starting, stopping or changing it with your prescriber.




